Company: AEMD
Filing Date: 2025-10-22
Form Type: 8-K
Source: 0001683168-25-007719
Chunk: 0

Company: AETHLON MEDICAL INC
Filing Date: 2025-10-22
Form: 8-K
Item: Item 3.01
Chunk 0
---
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.

On October 16, 2025, Aethlon Medical, Inc. (the
“ Company”) received a notification letter (the “ Notice”) from the Listing Qualifications Department (the “ Staff”)
of the Nasdaq Stock Market LLC (“ Nasdaq”) notifying the Company that, because the closing bid price for the Company’s
common stock was below $1.00 per share for 30 consecutive business days, the Company was not in compliance with the minimum bid price
requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “ Minimum
Bid Price Requirement”) and subject to the compliance and delisting provisions of Rule 5810(c)(3)(A) and (iv) thereunder.

The Company has filed a request for a hearing
before the Nasdaq Hearings Panel (the “ Panel”). The hearing request will automatically stay any suspension or delisting action
by Nasdaq pending the panel’s decision, and the Company’s common stock will continue to trade on Nasdaq Capital Market under
the symbol “ AEMD”.

As part of its plan to regain compliance with
Nasdaq listing requirements, the Company has already implemented a 1-for-10 reverse stock split of its common stock, which became effective
on October 16 and began trading on October 20, 2025. The Company is monitoring the closing bid price of its common stock and will evaluate
additional actions as appropriate to maintain its listing on the Nasdaq Capital Market.

Forward-Looking Statements